Medscape is available in 5 Language Editions – Choose your Edition here.


Familial Glucocorticoid Deficiency Clinical Presentation

  • Author: Andrea Haqq, MD; Chief Editor: Stephen Kemp, MD, PhD  more...
Updated: Sep 25, 2013


Focus the history on symptoms compatible with glucocorticoid deficiency such as hypoglycemia and shock. Children with hypoglycemia can present with pallor, sweating, palpitations, anxiety, shakiness, hunger, abdominal symptoms, vision changes, or changes in mental status such as confusion, mood changes, lethargy, seizures, and coma. In newborns, symptoms of hypoglycemia can be subtle; a high index of suspicion is needed. Newborns can present with irritability, jitteriness, respiratory distress, cyanosis, apnea, hypotonia, or seizures. A history of failure to thrive, poor feeding, absence of weight gain, lethargy, and recurrent or severe infections due to glucocorticoid deficiency suggest familial glucocorticoid deficiency (FGD). A positive family history of consanguinity or early unexplained infant deaths or other affected family members supports a diagnosis of FGD.

Patients with FGD generally present with signs and symptoms of adrenal insufficiency with the important distinction that mineralocorticoid production is always normal. The most common initial presenting sign is deep hyperpigmentation of the skin,[11] mucous membranes, or both as a result of the action of adrenocorticotropic hormone (ACTH) on cutaneous melanocyte-stimulating hormone (MSH) receptors. Many patients present with recurrent hypoglycemia or severe infections, although these are not the most common initial presenting signs. In the neonatal period, frequent presenting signs include feeding problems, failure to thrive, regurgitation, and hypoglycemia manifesting as seizures. The hypoglycemia-related seizures may be fatal. Finally, hypoglycemia, lethargy, seizures, shock, or sudden death may be the initial presentation in early childhood. Some children present with tall stature.



Distinguish FGD from other disorders that cause adrenal insufficiency.

  • Positive findings
    • Focus the physical examination of individuals with FGD on eliciting signs of ACTH excess and glucocorticoid deficiency.
    • The most striking physical examination finding may be the presence of excess pigmentation of skin, areolae, genitalia, and mucous membranes. The deep pigmentation of the skin is the result of the action of ACTH on cutaneous MSH receptors.
    • Signs of isolated glucocorticoid deficiency may be present on physical examination. These include lethargy, decreased level of consciousness, and muscle weakness.
    • Blood pressure and hemodynamic status may be preserved in these patients because of normal mineralocorticoid function.
    • Tall stature, advanced bone age, or both have been described in some children with FGD. Not all patients with the same ACTH receptor mutation manifest tall stature. To date, growth hormone levels and adrenal androgens have been within the reference range in these children. At this time, the mechanism for this increase in height and advanced bone age in FGD is unknown. Possible explanations for this phenomenon have included an effect of elevated ACTH levels on the MSH receptors in cartilaginous growth plates or an effect of excess ACTH stimulating estradiol synthesis or acting on bone growth factors such as aromatase. For example, a patient with FGD type 2 and an elevated estradiol level that was related to the increase in plasma ACTH has been described. Alternatively, the anabolic properties of growth hormone unopposed by cortisol may result in this increase in height.
  • Negative findings
    • Absence of ambiguous genitalia or congenital adrenal hyperplasia
    • Absence of cutaneous candidiasis or polyglandular autoimmune syndrome
    • Absence of alacrima and achalasia or Allgrove syndrome (AS)
    • Neurologic signs such as observed in AS, adrenoleukodystrophy, and Wolman disease
    • Absence of adrenarche is a feature typical of children with FGD
  • An important distinction should be made between FGD and AS (AAA syndrome), another rare autosomal recessive disease. Although both of these syndromes are characterized by glucocorticoid deficiency, AS has the additional features of alacrima (absence of tears), achalasia of the cardia, and a wide spectrum of neurologic abnormalities. AS is discussed in Allgrove (AAA) Syndrome.


Patients with FGD present with an isolated defect in glucocorticoid production. Because ACTH levels are in fact elevated, the apparent defect was hypothesized to be signaling either in the ACTH receptor or in post–ACTH receptor mechanisms. Alternatively, an isolated defect in the development of the adrenal zona fasciculata can also result in isolated deficiency of glucocorticoid production.

  • DNA analysis of all patients with FGD has demonstrated that only about 25-40% of these patients have mutations in the ACTH receptor gene. Dividing FGD into the following subcategories has been proposed: type 1 (with ACTH receptor mutations), type 2 (with mutations in the MC2 receptor accessory protein [MRAP] but a normal ACTH receptor), and type 3 and others.
  • Allgrove syndrome is a completely separate entity. The presence of mineralocorticoid deficiency in some cases of AS, frequent association with progressive and variable neurologic impairment, and different underlying genetic etiology clearly distinguish AS from FGD.
  • Type 1 FGD is associated with ACTH receptor mutations (approximately 25-40% of FGD cases).
    • Mountjoy et al reported the cloning of the human ACTH receptor in 1992.[12] Defects in the ACTH receptor, a small G protein–coupled receptor, have been described in families and individuals in whom a clinical diagnosis of FGD has been suspected. In 1993, Clark et al were the first to report a point mutation (S741) in the human ACTH receptor that resulted in a serine substitution for the normal amino acid at site 741 in a male proband of an FGD family.[13] A similar defect was found in an affected sister and a normal sequence in an unaffected brother. Both parents were heterozygous for this defect. This mutation segregated with the disease in an autosomal recessive fashion. Furthermore, this mutation was found to decrease the ability of ACTH to bind to the ACTH receptor in vivo.
    • Several other human ACTH receptor point mutations have been functionally characterized. Several classes of defects were observed. Most of these mutations caused a decrease in the ability of ACTH to bind to the ACTH receptor.
    • Other mutations were found to not only decrease the ability of ACTH to bind to the ACTH receptor (MC2R) but also to lead to defects in downstream signal transduction. For example, several MC2R mutations that cause loss of ligand binding (D103N, D107N, I118fs, T159K, I44M, C251F), structural disruption (S741, S120R, T159K, P273H, A126S), impairment of disulfide bonds (C251F, T254C), truncated receptor (1052delC, 1272delTA, R201X, 1347insA, L192fs, G217fs, F119fs), or loss of signal transduction (I44M, R128C, R146H, V142L, R137W, G116V) have been described. At least two compound heterozygous mutations in the ACTH receptor have now been reported (S74I and T159K; C21Y and R146H).
    • A poor correlation between severity of gene defect and clinical phenotype has been observed.
    • Even with identical mutations of the human MC2R, considerable variation in clinical phenotype is observed. In general, correlation was poor between the estimated severity of the receptor defect in vitro and the age at clinical presentation and disease severity, as judged by basal and stimulated plasma cortisol levels.
    • When the clinical characteristics of FGD associated with an ACTH receptor mutation were compared with FGD associated with no known mutation, no significant differences were observed in either the age of presentation of the patients or in the symptoms present at diagnosis. In addition, cortisol values were comparable between these two subtypes. The only significant difference found between the two subtypes was a difference in the stature of these patients. All the patients presenting with above-average height standard deviation scores originated from the FGD ACTH receptor mutation–positive group. All measurements of growth hormone and insulin-like growth factor 1 (IGF-1) in these patients have been within the reference range to date.
  • Type 2 FGD is due to mutations in MRAP (approximately 15-20% of FGD cases).
    • As a result of studying many families with FGD, mutations within the coding region of the ACTH receptor are recognized to account for the underlying defect in only some cases. That raised the possibility that defects may be located in the regulatory region of the ACTH receptor or that defects occur in other genes, such as cofactors of the ACTH receptor.
    • Metherall and colleagues conducted a whole-genome scan by microarray analysis of single nucleotide polymorphisms (SNPs) using genomic DNA from parents, affected children, and unaffected siblings who manifest FGD type 2.[14, 15] A single candidate region emerged at chromosome 21q22.1, with a maximum load score of 2.64. Further analysis identified a gene localized to this interval and expressed in the adrenal cortex. This gene has now been renamed MRAP. The MRAP gene consists of 6 exons and alternative splicing of exon 5 or 6 gives rise to two protein isoforms of 19 kDa and 14.1 kDa, respectively.
    • Mutations in MRAP have now been identified in families with FGD type 2 (approximately 15-20% of FGD cases). At least 8 different mutations in MRAP have been documented in these patients.
    • In vitro analysis further shows that MRAP and MC2R interact physically and are both colocalized in the endoplasmic reticulum and plasma membrane. Furthermore, MRAP is required for MC2R expression in certain cell types, suggesting that MRAP plays a role in processing, trafficking, or function of the MC2R.
  • Type 3 and type 4 FGD are due to additional genes.
    • Because FGD now seems likely to be caused by multiple genetic defects, other possible candidate genes might include the following:
      • Genes involving ACTH signal transduction. Because many of these genes are fundamental mediators of signal transduction in multiple tissues, a mutation that would cause a disorder restricted to only the adrenal gland seems unlikely.
      • Gene-specific transcription factors or translational regulators affecting ACTH receptor expression. The further characterization of the ACTH receptor promoter will eventually shed light on this possibility.
      • Genes coding for differentiation factors of the adrenal cortex. As yet, these factors are not well-characterized. However, one might postulate that failure of differentiation of fasciculata and reticularis cells only with normal glomerulosa cell differentiation may result in FGD.
    • Linkage of genes on chromosome 8q to FGD has been described, implicating another gene in this disorder.
  • AS or AAA syndrome is associated with alacrima and achalasia.
    • First described in 1978 by Allgrove et al,[16] AAA syndrome is characterized by glucocorticoid deficiency, alacrima, achalasia of the cardia, and a wide spectrum of neurologic abnormalities. Alacrima is often manifest at birth, and patients may present with conjunctival injection and irritation. If alacrima is unrecognized, it may lead to severe keratopathy and corneal melting (dehydration-induced ulceration). Achalasia is a neuromuscular disorder of the esophagus resulting in elevated lower esophageal sphincter (LES) pressure, incomplete relaxation of the LES, and aperistalsis of the body of the esophagus. In childhood, achalasia may result in complications of severe lung disease, growth retardation, and respiratory death. However, not all children with achalasia have AS.
    • In one study, 1 out of the 35 children with achalasia had AS.[17] Other neurologic abnormalities have been associated with AS, including distal motor and sensory neuropathy, dysarthria, ataxia, Parkinsonian disease features, mild dementia, developmental delay, and optic atrophy.
    • AS is inherited as an autosomal recessive trait. Using genetic linkage analysis, a causative locus was identified on chromosome 12q13. The AAA gene identified at this locus is called ALADIN and belongs to the WD-repeat family of regulatory proteins. The expression of this gene in neuroendocrine and neuronal structures suggests its role in normal development of the peripheral nervous system and the CNS.
    • For further details, see Allgrove (AAA) Syndrome.
Contributor Information and Disclosures

Andrea Haqq, MD Assistant Professor, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Duke University Medical Center

Andrea Haqq, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, American College of Endocrinology

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Thomas A Wilson, MD Professor of Clinical Pediatrics, Chief and Program Director, Division of Pediatric Endocrinology, Department of Pediatrics, The School of Medicine at Stony Brook University Medical Center

Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Pediatric Endocrine Society, Phi Beta Kappa

Disclosure: Nothing to disclose.


Bruce A Boston, MD Chief, Division of Pediatric Endocrinology, Director, Pediatric Endocrine Training Program, Associate Professor, Department of Pediatrics, Division of Pediatric Endocrinology, Oregon Health Sciences University and Doernbecher Children's Hospital

Bruce A Boston, MD is a member of the following medical societies: Alpha Omega Alpha, American Diabetes Association, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

  1. Shepard TH, Landing BH, Mason DG. Familial Addison's disease; case reports of two sisters with corticoid deficiency unassociated with hypoaldosteronism. AMA J Dis Child. 1959 Feb. 97(2):154-62. [Medline].

  2. Migeon CJ, Kenny EM, Kowarski A, et al. The syndrome of congenital adrenocortical unresponsiveness to ACTH. Report of six cases. Pediatr Res. 1968 Nov. 2(6):501-13. [Medline].

  3. Kelch RP, Kaplan SL, Biglieri EG, et al. Hereditary adrenocortical unresponsiveness to adrenocorticotropic hormone. The J of Pediatrics. 1972. 81:726-736. [Medline].

  4. Moshang T Jr, Rosenfield RL, Bongiovanni AM, Parks JS, Amrhein JA. Familial glucocorticoid insufficiency. J Pediatr. 1973 May. 82(5):821-6. [Medline].

  5. Thistlethwaite D, Darling JA, Fraser R, et al. Familial glucocorticoid deficiency. Studies of diagnosis and pathogenesis. Arch Dis Child. 1975 Apr. 50(4):291-7. [Medline].

  6. Spark RF, Etzkorn JR. Absent aldosterone response to ACTH in familial glucocorticoid deficiency. N Engl J Med. 1977 Oct 27. 297(17):917-20. [Medline].

  7. Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet. 2012 May 27. 44(7):740-2. [Medline]. [Full Text].

  8. Meimaridou E, Hughes CR, Kowalczyk J, Guasti L, Chapple JP, King PJ, et al. Familial glucocorticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol. 2013 May 22. 371(1-2):195-200. [Medline].

  9. Jain V, Metherell LA, David A, Sharma R, Sharma PK, Clark AJ, et al. Neonatal presentation of familial glucocorticoid deficiency resulting from a novel splice mutation in the melanocortin 2 receptor accessory protein. Eur J Endocrinol. 2011 Dec. 165(6):987-91. [Medline]. [Full Text].

  10. Aza-Carmona M, Barreda-Bonis AC, Guerrero-Fernández J, González-Casado I, Gracia R, Heath KE. Familial glucocorticoid deficiency due to compound heterozygosity of two novel MC2R mutations. J Pediatr Endocrinol Metab. 2011. 24(5-6):395-7. [Medline].

  11. Shivaprasad KS, Dutta D, Jain R, Ghosh S, Mukhopadhyay S, Chowdhury S. Familial glucocorticoid deficiency presenting with generalized hyperpigmentation in adolescence. Report of three siblings. Indian J Endocrinol Metab. 2012 Dec. 16:S382-4. [Medline]. [Full Text].

  12. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992 Aug 28. 257(5074):1248-51. [Medline].

  13. Clark AJ, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet. 1993 Feb 20. 341(8843):461-2. [Medline].

  14. Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet. 2005 Feb. 37(2):166-70. [Medline].

  15. Metherell LA, Cooray S, Huebner A, et al. Mutations in a novel gene, encoding a single transmembrane domain protein are associated with familial glucocorticoid deficiency type 2. Endocr Res. 2004 Nov. 30(4):889-90. [Medline].

  16. Allgrove J, Clayden GS, Grant DB, Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet. 1978 Jun 17. 1(8077):1284-6. [Medline].

  17. Nihoul-Fekete C, Bawab F, Lortat-Jacob S, Arhan P. Achalasia of the esophagus in childhood. Surgical treatment in 35 cases, with special reference to familial cases and glucocorticoid deficiency association. Hepatogastroenterology. 1991 Dec. 38(6):510-3. [Medline].

  18. Allolio B, Reincke M. Adrenocorticotropin receptor and adrenal disorders. Horm Res. 1997. 47(4-6):273-8. [Medline].

  19. Artigas RA, Gonzalez A, Riquelme E, et al. A novel adrenocorticotropin receptor mutation alters its structure and function, causing familial glucocorticoid deficiency. J Clin Endocrinol Metab. 2008 Aug. 93(8):3097-105. [Medline].

  20. Chan LF, Clark AJ, Metherell LA. Familial glucocorticoid deficiency: advances in the molecular understanding of ACTH action. Horm Res. 2008. 69(2):75-82. [Medline].

  21. Clark AJ, Cammas FM, Watt A, Kapas S, Weber A. Familial glucocorticoid deficiency: one syndrome, but more than one gene. J Mol Med. 1997 Jun. 75(6):394-9. [Medline].

  22. Elias LL, Huebner A, Metherell LA, et al. Tall stature in familial glucocorticoid deficiency. Clin Endocrinol (Oxf). 2000 Oct. 53(4):423-30. [Medline].

  23. Elias LL, Huebner A, Pullinger GD, Mirtella A, Clark AJ. Functional characterization of naturally occurring mutations of the human adrenocorticotropin receptor: poor correlation of phenotype and genotype. J Clin Endocrinol Metab. 1999 Aug. 84(8):2766-70. [Medline].

  24. Grant DB, Dunger DB, Smith I, Hyland K. Familial glucocorticoid deficiency with achalasia of the cardia associated with mixed neuropathy, long-tract degeneration and mild dementia. Eur J Pediatr. 1992 Feb. 151(2):85-9. [Medline].

  25. Heinrichs C, Tsigos C, Deschepper J, et al. Familial adrenocorticotropin unresponsiveness associated with alacrima and achalasia: biochemical and molecular studies in two siblings with clinical heterogeneity. Eur J Pediatr. 1995 Mar. 154(3):191-6. [Medline].

  26. Houlden H, Smith S, De Carvalho M, et al. Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain. 2002 Dec. 125:2681-90. [Medline]. [Full Text].

  27. Huebner A, Elias LL, Clark AJ. ACTH resistance syndromes. J Pediatr Endocrinol Metab. 1999 Apr. 12 Suppl 1:277-93. [Medline].

  28. Imamine H, Mizuno H, Sugiyama Y, et al. Possible relationship between elevated plasma ACTH and tall stature in familial glucocorticoid deficiency. Tohoku J Exp Med. 2005 Feb. 205(2):123-31. [Medline].

  29. Kershnar AK, Roe TF, Kogut MD. Adrenocorticotropic hormone unresponsiveness: report of a girl with excessive growth and review of 16 reported cases. J Pediatr. 1972 Apr. 80(4):610-9. [Medline].

  30. Matsuura H, Shiohara M, Yamano M, Kurata K, Arai F, Koike K. Novel compound heterozygous mutation of the MC2R gene in a patient with familial glucocorticoid deficiency. J Pediatr Endocrinol Metab. 2006 Sep. 19(9):1167-70. [Medline].

  31. Metherell LA, Chan LF, Clark AJ. The genetics of ACTH resistance syndromes. Best Pract Res Clin Endocrinol Metab. 2006 Dec. 20(4):547-60. [Medline].

  32. Modan-Moses D, Ben-Zeev B, Hoffmann C, et al. Unusual presentation of familial glucocorticoid deficiency with a novel MRAP mutation. J Clin Endocrinol Metab. 2006 Oct. 91(10):3713-7. [Medline].

  33. Moshang T Jr. Familial glucocorticoid deficiency. N Engl J Med. 1978 Feb 2. 298(5):282-3. [Medline].

  34. Naville D, Barjhoux L, Jaillard C, et al. Stable expression of normal and mutant human ACTH receptor: study of ACTH binding and coupling to adenylate cyclase. Mol Cell Endocrinol. 1997 Apr 25. 129(1):83-90. [Medline].

  35. Naville D, Weber A, Genin E, et al. Exclusion of the adrenocorticotropin (ACTH) receptor (MC2R) locus in some families with ACTH resistance but no mutations of the MC2R coding sequence (familial glucocorticoid deficiency type 2). J Clin Endocrinol Metab. 1998 Oct. 83(10):3592-6. [Medline]. [Full Text].

  36. New MI, Rapaport R, Sperling MA. Adrenal insufficiency. Pediatric Endocrinology. WB Saunders; 1996. 301-305.

  37. O'Riordan SM, Lynch SA, Hindmarsh PC, Chan LF, Clark AJ, Costigan C. A novel variant of familial glucocorticoid deficiency prevalent among the Irish Traveler population. J Clin Endocrinol Metab. 2008 Jul. 93(7):2896-9. [Medline].

  38. Ramachandran P, Penhoat A, Naville D, et al. Familial glucocorticoid deficiency type 2 in two neonates. J Perinatol. 2003 Jan. 23(1):62-6. [Medline].

  39. Selva KA, LaFranchi SH, Boston B. A novel presentation of Familial Glucocorticoid Deficiency (FGD) and current literature review. J Pediatr Endocrinol Metab. 2004. 17:85-92. [Medline].

  40. Shah BR, Fiordalisi I, Sheinbaum K, Finberg L. Familial glucocorticoid deficiency in a girl with familial hypophosphatemic rickets. Am J Dis Child. 1988 Aug. 142(8):900-3. [Medline].

  41. Slavotinek AM, Hurst JA, Dunger D, Wilkie AO. ACTH receptor mutation in a girl with familial glucocorticoid deficiency. Clin Genet. 1998 Jan. 53(1):57-62. [Medline].

  42. Stempfel RS, Engel FL. A congenital familial syndrome of adrenocortical insufficiency without hypoaldosteronism. J Pediatr. 1960. 57:443-451. [Full Text].

  43. Tanae A, Aoyama M, Egi S, Imai M, Yoshihara S. Familial Addison's disease. Clinical studies on three cases of the same family. Acta Paediatr Jpn. 1971 Dec. 13(2):1-12. [Medline].

  44. Tsigos C, Arai K, Hung W, Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest. 1993 Nov. 92(5):2458-61. [Medline]. [Full Text].

  45. Tullio-Pelet A, Salomon R, Hadj-Rabia S, et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet. 2000 Nov. 26(3):332-5. [Medline].

  46. Weber A, Clark AJ. Mutations of the ACTH receptor gene are only one cause of familial glucocorticoid deficiency. Hum Mol Genet. 1994 Apr. 3(4):585-8. [Medline].

  47. Weber A, Kapas S, Hinson J, et al. Functional characterization of the cloned human ACTH receptor: impaired responsiveness of a mutant receptor in familial glucocorticoid deficiency. Biochem Biophys Res Commun. 1993 Nov 30. 197(1):172-8. [Medline].

  48. Weber A, Toppari J, Harvey RD, et al. Adrenocorticotropin receptor gene mutations in familial glucocorticoid deficiency: relationships with clinical features in four families. J Clin Endocrinol Metab. 1995 Jan. 80(1):65-71. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.